{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T06:51:21Z","timestamp":1770015081045,"version":"3.49.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Plan Nacional de I+D+i"},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Subdirecci\u00f3n General de Redes y Centros de Investigaci\u00f3n Cooperativa"},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish Network for Research in Infectious Diseases","award":["REIPI RD12\/0015"],"award-info":[{"award-number":["REIPI RD12\/0015"]}]},{"name":"European Development Regional Fund"},{"name":"Andalusia Health and Social Welfare Ministry","award":["PI-0058-2012"],"award-info":[{"award-number":["PI-0058-2012"]}]},{"name":"Fundaci\u00f3n Andaluza para la Gesti\u00f3n de la Investigaci\u00f3n en Salud de Sevilla"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.drudis.2015.07.007","type":"journal-article","created":{"date-parts":[[2015,7,23]],"date-time":"2015-07-23T02:05:57Z","timestamp":1437617157000},"page":"1235-1242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Antiadenovirus drug discovery: potential targets and evaluation methodologies"],"prefix":"10.1016","volume":"20","author":[{"given":"Pablo","family":"Mart\u00ednez-Aguado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Serna-Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Marrugal-Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"G\u00f3mez-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2707-1979","authenticated-orcid":false,"given":"Javier","family":"S\u00e1nchez-C\u00e9spedes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2015.07.007_bib0570","first-page":"479","article-title":"Viral infections in transplant recipients","volume":"100","author":"Razonable","year":"2009","journal-title":"Minerva Med."},{"key":"10.1016\/j.drudis.2015.07.007_bib0575","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/tid.12022","article-title":"European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011)","volume":"14","author":"Matthes-Martin","year":"2012","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.drudis.2015.07.007_bib0580","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/rmv.589","article-title":"Clinical features and treatment of adenovirus infections","volume":"18","author":"Lenaerts","year":"2008","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0585","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1586\/14787210.2013.836964","article-title":"Diagnosis and treatment of adenovirus infection in immunocompromised patients","volume":"11","author":"Matthes-Martin","year":"2013","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"10.1016\/j.drudis.2015.07.007_bib0590","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/CMR.00116-13","article-title":"Adenovirus infections in immunocompetent and immunocompromised patients","volume":"27","author":"Lion","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.drudis.2015.07.007_bib0595","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/135965350501000204","article-title":"In vitro susceptibility of adenovirus to antiviral drugs is species-dependent","volume":"10","author":"Morfin","year":"2005","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.drudis.2015.07.007_bib0600","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1128\/AAC.49.3.1010-1016.2005","article-title":"Antiadenovirus activities of several classes of nucleoside and nucleotide analogues","volume":"49","author":"Naesens","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drudis.2015.07.007_bib0605","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.antiviral.2006.04.007","article-title":"Antiviral therapy for adenovirus infections","volume":"71","author":"Lenaerts","year":"2006","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drudis.2015.07.007_bib0610","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-4615-4743-3_10","article-title":"Cidofovir. Review of current and potential clinical uses","volume":"458","author":"Safrin","year":"1999","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0615","series-title":"Principles & Practice of Pediatric Infectious Diseases","first-page":"562","article-title":"Infections in hematopoietic stem cell transplant recipients","author":"Lujan-Zilbermann","year":"2008"},{"key":"10.1016\/j.drudis.2015.07.007_bib0620","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.antiviral.2014.05.010","article-title":"Inhibition of adenovirus replication by a trisubstituted piperazin-2-one derivative","volume":"108","author":"Sanchez-Cespedes","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drudis.2015.07.007_bib0625","article-title":"Marketing authorisation for Vistide withdrawn","volume":"293","year":"2014","journal-title":"Pharm. J."},{"key":"10.1016\/j.drudis.2015.07.007_bib0630","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/leu.2010.4","article-title":"Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation","volume":"24","author":"Lion","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2015.07.007_bib0635","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1182\/blood-2010-04-259291","article-title":"How I treat adenovirus in hematopoietic stem cell transplant recipients","volume":"116","author":"Lindemans","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2015.07.007_bib0640","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1097\/01.tp.0000209195.95115.8e","article-title":"Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients","volume":"81","author":"Yusuf","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.drudis.2015.07.007_bib0645","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1399-3062.2006.00184.x","article-title":"Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir","volume":"9","author":"Symeonidis","year":"2007","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.drudis.2015.07.007_bib0650","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1399-3062.2009.00391.x","article-title":"Safety and tolerability of cidofovir in high-risk pediatric patients","volume":"11","author":"Bhadri","year":"2009","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.drudis.2015.07.007_bib0655","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drudis.2015.07.007_bib0660","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1073\/pnas.0800200105","article-title":"Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model","volume":"105","author":"Toth","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2015.07.007_bib0665","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.05983-11","article-title":"First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses","volume":"56","author":"Painter","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drudis.2015.07.007_bib0670","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0675","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/135965350901400110","article-title":"Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone","volume":"14","author":"Morfin","year":"2009","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.drudis.2015.07.007_bib0680","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/319984","article-title":"Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"32","author":"Bordigoni","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drudis.2015.07.007_bib0685","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bmt.1700997","article-title":"Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir","volume":"20","author":"Chen","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.drudis.2015.07.007_bib0690","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/095632020401500507","article-title":"Therapeutic basis of vidarabine on adenovirus-induced haemorrhagic cystitis","volume":"15","author":"Kurosaki","year":"2004","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.drudis.2015.07.007_bib0695","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1083-8791(03)00102-2","article-title":"Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival","volume":"9","author":"Bruno","year":"2003","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.drudis.2015.07.007_bib0700","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/sj.bmt.1704216","article-title":"Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation","volume":"32","author":"Vij","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.drudis.2015.07.007_bib0705","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.1128\/AAC.03860-14","article-title":"Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters","volume":"58","author":"Ying","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drudis.2015.07.007_bib0710","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3390\/v7031409","article-title":"Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters","volume":"7","author":"Toth","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2015.07.007_bib0715","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-398342-8.00003-3","article-title":"Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds","volume":"115","author":"Wold","year":"2012","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.drudis.2015.07.007_bib0720","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2002-02-0377","article-title":"Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery","volume":"100","author":"Chakrabarti","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2015.07.007_bib0725","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri1526","article-title":"Cellular immunotherapy for viral infection after HSC transplantation","volume":"5","author":"Moss","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0730","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/JVI.01689-07","article-title":"Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy","volume":"82","author":"Leen","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0735","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drudis.2015.07.007_bib0740","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1084\/jem.20011692","article-title":"Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein\u2013Barr virus infection","volume":"195","author":"Hislop","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drudis.2015.07.007_bib0745","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/mt.2009.140","article-title":"Nucleofection of DCs to generate multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host","volume":"17","author":"Gerdemann","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2015.07.007_bib0750","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3109\/14653249.2011.575356","article-title":"Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein\u2013Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation","volume":"13","author":"Hanley","year":"2011","journal-title":"Cytotherapy"},{"key":"10.1016\/j.drudis.2015.07.007_bib0755","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3324\/haematol.2010.022947","article-title":"Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection","volume":"95","author":"Zandvliet","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2015.07.007_bib0760","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2006.06108.x","article-title":"Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation","volume":"134","author":"Feuchtinger","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0765","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clim.2013.01.002","article-title":"Selection of perforin expressing CD4+ adenovirus-specific T-cells with artificial antigen presenting cells","volume":"146","author":"Haveman","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0770","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol. Ther."},{"issue":"51","key":"10.1016\/j.drudis.2015.07.007_bib0775","first-page":"e2736","article-title":"Generation of multivirus-specific T cells to prevent\/treat viral infections after allogeneic hematopoietic stem cell transplant","author":"Gerdemann","year":"2011","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.drudis.2015.07.007_bib0780","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12967-014-0336-5","article-title":"Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells","volume":"12","author":"Tischer","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.drudis.2015.07.007_bib0785","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/mt.2014.192","article-title":"Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells","volume":"23","author":"Melenhorst","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2015.07.007_bib0790","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2015.07.007_bib0795","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2015.07.007_bib0800","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00002371-200407000-00007","article-title":"Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases","volume":"27","author":"Wilkie","year":"2004","journal-title":"J. Immunother."},{"key":"10.1016\/j.drudis.2015.07.007_bib0805","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.febslet.2013.05.033","article-title":"First generation inhibitors of the adenovirus proteinase","volume":"587","author":"McGrath","year":"2013","journal-title":"FEBS Lett."},{"key":"10.1016\/j.drudis.2015.07.007_bib0810","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0166-3542(01)00167-X","article-title":"Antiviral activity of NMSO3 against adenovirus in vitro","volume":"52","author":"Kaneko","year":"2001","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drudis.2015.07.007_bib0815","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jviromet.2009.11.020","article-title":"Real time PCR for rapid determination of susceptibility of adenovirus to antiviral drugs","volume":"164","author":"Gainotti","year":"2010","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.drudis.2015.07.007_bib0820","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.chom.2007.12.001","article-title":"Mechanism of adenovirus neutralization by human alpha-defensins","volume":"3","author":"Smith","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.drudis.2015.07.007_bib0825","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1128\/JVI.02321-10","article-title":"Functional genetic and biophysical analyses of membrane disruption by human adenovirus","volume":"85","author":"Moyer","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0830","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.chom.2013.09.004","article-title":"Tracking viral genomes in host cells at single-molecule resolution","volume":"14","author":"Wang","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.drudis.2015.07.007_bib0835","doi-asserted-by":"crossref","first-page":"12367","DOI":"10.1128\/JVI.01833-13","article-title":"A direct and versatile assay measuring membrane penetration of adenovirus in single cells","volume":"87","author":"Suomalainen","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0840","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1743-422X-6-174","article-title":"Genetic reconstitution of the human adenovirus type 2 temperature-sensitive 1 mutant defective in endosomal escape","volume":"6","author":"Imelli","year":"2009","journal-title":"Virol. J."},{"key":"10.1016\/j.drudis.2015.07.007_bib0845","doi-asserted-by":"crossref","first-page":"10123","DOI":"10.1128\/JVI.01102-12","article-title":"Cell-free transmission of human adenovirus by passive mass transfer in cell culture simulated in a computer model","volume":"86","author":"Yakimovich","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0850","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/adt.2004.2.363","article-title":"Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays","volume":"2","author":"Solly","year":"2004","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0855","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1128\/JVI.01571-10","article-title":"Stepwise loss of fluorescent core protein V from human adenovirus during entry into cells","volume":"85","author":"Puntener","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0860","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1016\/j.bmc.2008.04.068","article-title":"Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds","volume":"16","author":"Prado-Prado","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2015.07.007_bib0865","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/jgm.1453","article-title":"Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir","volume":"12","author":"Diaconu","year":"2010","journal-title":"J. Gene Med."},{"key":"10.1016\/j.drudis.2015.07.007_bib0870","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2014.10.005","article-title":"Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model","volume":"112","author":"Tollefson","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drudis.2015.07.007_bib0875","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1128\/AAC.49.11.4689-4699.2005","article-title":"Mouse adenovirus type 1 infection in SCID mice: an experimental model for antiviral therapy of systemic adenovirus infections","volume":"49","author":"Lenaerts","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drudis.2015.07.007_bib0880","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1128\/JVI.80.7.3549-3558.2006","article-title":"Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species","volume":"80","author":"Jogler","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0885","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1128\/JVI.79.2.1308-1311.2005","article-title":"Productive replication of human adenovirus type 5 in canine cells","volume":"79","author":"Ternovoi","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0890","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/jac\/dki057","article-title":"Prospects for adenovirus antivirals","volume":"55","author":"Kinchington","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drudis.2015.07.007_bib0895","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/hum.2005.16.139","article-title":"Cotton rat tumor model for the evaluation of oncolytic adenoviruses","volume":"16","author":"Toth","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.drudis.2015.07.007_bib0900","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1128\/jvi.67.1.101-111.1993","article-title":"Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus)","volume":"67","author":"Prince","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0905","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.virol.2008.10.016","article-title":"Insights into adenovirus host cell interactions from structural studies","volume":"384","author":"Nemerow","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.drudis.2015.07.007_bib0910","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2015.07.007_bib0915","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.drudis.2015.07.007_bib0920","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2015.07.007_bib0925","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1128\/JVI.06181-11","article-title":"Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection","volume":"86","author":"Trinh","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0930","first-page":"195","article-title":"Adenovirus","volume":"343","author":"Smith","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0935","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1743-422X-7-148","article-title":"Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cells","volume":"7","author":"Lyle","year":"2010","journal-title":"Virol. J."},{"key":"10.1016\/j.drudis.2015.07.007_bib0940","doi-asserted-by":"crossref","first-page":"7806","DOI":"10.1128\/JVI.00896-14","article-title":"A small molecule inhibits virion attachment to heparan sulfate- or sialic acid-containing glycans","volume":"88","author":"Colpitts","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0945","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1006\/viro.1999.0171","article-title":"Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions","volume":"268","author":"Dechecchi","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.drudis.2015.07.007_bib0950","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000104763","article-title":"Antiadenoviral effect of the alpha 5 beta 1 integrin receptor ligand, GRGDSP peptide, in serotypes that cause acute keratoconjunctivitis","volume":"221","author":"Uchio","year":"2007","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.drudis.2015.07.007_bib0955","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1128\/AAC.47.8.2688-2691.2003","article-title":"Bovine lactoferrin inhibits adenovirus infection by interacting with viral structural polypeptides","volume":"47","author":"Pietrantoni","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drudis.2015.07.007_bib0960","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0166-3542(02)00021-9","article-title":"Adenovirus inhibition by peptidomimetic integrin antagonists","volume":"55","author":"Hippenmeyer","year":"2002","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drudis.2015.07.007_bib0965","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0092-8674(93)90382-Z","article-title":"Stepwise dismantling of adenovirus 2 during entry into cells","volume":"75","author":"Greber","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2015.07.007_bib0970","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1083\/jcb.144.4.657","article-title":"Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus","volume":"144","author":"Suomalainen","year":"1999","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0975","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1128\/JVI.00473-13","article-title":"Directed evolution of mutator adenoviruses resistant to antibody neutralization","volume":"87","author":"Myers","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0980","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1128\/JVI.00557-08","article-title":"Neutralizing antibody blocks adenovirus infection by arresting microtubule-dependent cytoplasmic transport","volume":"82","author":"Smith","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib0985","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1091\/mbc.e05-02-0121","article-title":"Nuclear targeting of adenovirus type 2 requires CRM1-mediated nuclear export","volume":"16","author":"Strunze","year":"2005","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.drudis.2015.07.007_bib0990","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.chom.2011.08.010","article-title":"Kinesin-1-mediated capsid disassembly and disruption of the nuclear pore complex promote virus infection","volume":"10","author":"Strunze","year":"2011","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.drudis.2015.07.007_bib0995","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/ni.2548","article-title":"Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21","volume":"14","author":"McEwan","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drudis.2015.07.007_bib1000","doi-asserted-by":"crossref","first-page":"11006","DOI":"10.1128\/JVI.77.20.11006-11015.2003","article-title":"Strategic attack on host cell gene expression during adenovirus infection","volume":"77","author":"Zhao","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib1005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2012.03.011","article-title":"Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery","volume":"94","author":"Kneidinger","year":"2012","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drudis.2015.07.007_bib1010","series-title":"DNA Tumor Viruses: Control of Gene Expression and Replication","first-page":"37","article-title":"Adenovirus gene expression and replication: a historical review","author":"Pettersson","year":"1986"},{"key":"10.1016\/j.drudis.2015.07.007_bib1015","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1126\/science.1068943","article-title":"Transcription control by E1 A and MAP kinase pathway via Sur2 mediator subunit","volume":"296","author":"Stevens","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.drudis.2015.07.007_bib1020","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.1155544","article-title":"Adenovirus small e1a alters global patterns of histone modification","volume":"321","author":"Horwitz","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.drudis.2015.07.007_bib1025","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.chom.2014.10.004","article-title":"Adenovirus small E1A employs the lysine acetylases p300\/CBP and tumor suppressor Rb to repress select host genes and promote productive virus infection","volume":"16","author":"Ferrari","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.drudis.2015.07.007_bib1030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.antiviral.2010.08.002","article-title":"Inhibition of adenovirus infections by siRNA-mediated silencing of early and late adenoviral gene functions","volume":"88","author":"Eckstein","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drudis.2015.07.007_bib1035","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00705-007-0951-z","article-title":"Silencing E1A mRNA by RNA interference inhibits adenovirus replication","volume":"152","author":"Chung","year":"2007","journal-title":"Arch. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib1040","doi-asserted-by":"crossref","first-page":"9556","DOI":"10.1128\/JVI.79.15.9556-9565.2005","article-title":"Suppression of RNA interference by adenovirus virus-associated RNA","volume":"79","author":"Andersson","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib1045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1556\/AMicr.50.2003.1.9","article-title":"Adenain, the adenovirus endoprotease","volume":"50","author":"Weber","year":"2003","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"10.1016\/j.drudis.2015.07.007_bib1050","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.3390\/v6114536","article-title":"Structure, function and dynamics in adenovirus maturation","volume":"6","author":"Mangel","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2015.07.007_bib1055","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.bmcl.2014.12.057","article-title":"Structure-based design and optimization of potent inhibitors of the adenoviral protease","volume":"25","author":"Grosche","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2015.07.007_bib1060","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/ml500224t","article-title":"Discovery and structure-based optimization of adenain inhibitors","volume":"5","author":"Mac Sweeney","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2015.07.007_bib1065","doi-asserted-by":"crossref","first-page":"e1002976","DOI":"10.1371\/journal.ppat.1002976","article-title":"Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects","volume":"8","author":"Jurgeit","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.drudis.2015.07.007_bib1070","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1099\/0022-1317-75-10-2595","article-title":"Involvement of the vacuolar H(+)-ATPase in animal virus entry","volume":"75","author":"Perez","year":"1994","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib1075","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2217\/fvl.14.70","article-title":"Novel drugs targeting Toll-like receptors for antiviral therapy","volume":"9","author":"Patel","year":"2014","journal-title":"Future Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib1080","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/hum.2014.001","article-title":"Innate immunity to adenovirus","volume":"25","author":"Hendrickx","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.drudis.2015.07.007_bib1085","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1128\/JVI.01926-06","article-title":"Preferential activation of Toll-like receptor nine by CD46-utilizing adenoviruses","volume":"81","author":"Iacobelli-Martinez","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib1090","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.4049\/jimmunol.181.3.2134","article-title":"Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo","volume":"181","author":"Appledorn","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.drudis.2015.07.007_bib1095","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1126\/science.1226625","article-title":"Coagulation factor X activates innate immunity to human species C adenovirus","volume":"338","author":"Doronin","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.drudis.2015.07.007_bib1100","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature12118","article-title":"The TLR4 antagonist Eritoran protects mice from lethal influenza infection","volume":"497","author":"Shirey","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2015.07.007_bib1105","doi-asserted-by":"crossref","first-page":"e1003775","DOI":"10.1371\/journal.ppat.1003775","article-title":"SPOC1-mediated antiviral host cell response is antagonized early in human adenovirus type 5 infection","volume":"9","author":"Schreiner","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.drudis.2015.07.007_bib1110","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1128\/JVI.00469-14","article-title":"Sp100 isoform-specific regulation of human adenovirus 5 gene expression","volume":"88","author":"Berscheminski","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib1115","doi-asserted-by":"crossref","first-page":"11928","DOI":"10.1128\/JVI.00758-11","article-title":"Human cytomegalovirus infection causes degradation of Sp100 proteins that suppress viral gene expression","volume":"85","author":"Kim","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib1120","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1128\/JVI.06992-11","article-title":"Herpesvirus saimiri antagonizes nuclear domain 10-instituted intrinsic immunity via an ORF3-mediated selective degradation of cellular protein Sp100","volume":"86","author":"Full","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2015.07.007_bib1125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Na. Rev. Cancer"},{"key":"10.1016\/j.drudis.2015.07.007_bib1130","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1172\/JCI73805","article-title":"CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses","volume":"124","author":"Yamamoto","year":"2014","journal-title":"J. Clin. Invest."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644615002780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644615002780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:24:51Z","timestamp":1761222291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644615002780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":113,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1359644615002780"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2015.07.007","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiadenovirus drug discovery: potential targets and evaluation methodologies","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2015.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}